Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Decentralized approaches in TRAILBLAZER-ALZ 3

              Author:Yaari, Roy   Holdridge, Karen   Ferguson, Margaret   Wessels, Alette   Sims, John   

              Session Name:P7: Aging and Dementia: Therapeutics 1  

              Topic:Aging and Dementia  

              Program Number:P7.006  

              Author Institution:Eli Lilly and Company, Indianapolis, IN  Banner Alzheimer’s Institute, Phoenix, AZ  Cogstate Ltd, Melbourne, Australia  Irvine Clinical Research, Irvine, CA  

              Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101

              Author:Park, Lovingly   Maslyar, Daniel   Ward, Michael   Yeh, Felix   Long, Hua   Kurnellas, Michael   Vadhavkar, Mayura   Budda, Balasubrahmanyam   

              Session Name:P7: Aging and Dementia: Therapeutics 1  

              Topic:Aging and Dementia  

              Program Number:P7.007  

              Author Institution:Alector, Inc., South San Francisco, CA  

              HARBOR: ABBV-916 In Subjects With Early Alzheimer’s Disease Combined Multiple-Ascending Dose/Proof-Of-Concept Study Design

              Author:Watson, David   Lynch, Shau Yu   Florian, Hana   Wang, Deli   Bachhav, Sagar   Boiser, Joey   Bannon, Anthony   Stage, Edwin   Graff, Ole   

              Session Name:P7: Aging and Dementia: Therapeutics 1  

              Topic:Aging and Dementia  

              Program Number:P7.008  

              Author Institution:Alzheimer's Research and Treatment Center, Wellington, FL  Neuroscience Clinical Development, AbbVie Inc., North Chicago, IL  Statistics, AbbVie Inc., Buffalo Grove, IL  Clinical Pharmacology, AbbVie Inc., North Chicago, IL  Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, IL  Precision Medicine, AbbVie Inc., North Chicago, IL  Discovery, AbbVie Inc., North Chicago, IL  

              Alzheimer’s Disease Linkage to Evidence (AD-LINE) Study Early Results: Linking Real-World Claims Data to Phase III GRADUATE Study of Gantenerumab

              Author:Wallick, Chris   Fillit, Howard   Tcheremissine, Oleg   Abbass, Ibrahim M   Ng, Carmen   To, Tu My   Seleri, Sheila   

              Session Name:P7: Aging and Dementia: Therapeutics 1  

              Topic:Aging and Dementia  

              Program Number:P7.009  

              Author Institution:Genentech, Inc., a member of the Roche Group, South San Francisco, CA  Departments of Geriatric Medicine, Medicine, and Neuroscience, Icahn School of Medicine and Mt. Sinai, New York, NY  Atrium Health Behavioral Health Charlotte , Charlotte, NC  

              Multi-Modal Correlation Analyses From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

              Author:Palumbo, Joseph   Zhang, Jeffrey   Mahdavi, Kennedy   Venkatraman, Victoria   Becerra, Sergio   Haroon, Jonathan   Jordan, Kaya   Rindner, Elisabeth   Surya, Jean R.   Kuhn, Taylor   Pourat, Bijan   Jordan, Sheldon   

              Session Name:P7: Aging and Dementia: Therapeutics 1  

              Topic:Aging and Dementia  

              Program Number:P7.010  

              Author Institution:BioVie Inc., Carson City, NV  Princeton Pharmatech LLC, Princeton, NJ  The Regenesis Project, Santa Monica, CA  Cedar Sinai Medical Center, Los Angeles, CA